News in brief: Bevacizumab PBS access changes; Medicinal cannabis trial for children with advanced cancer; New opioid criteria for palliative care patients;

Bevacizumab biosimilar gains unrestricted PBS listing The biologic bevacizumab will be available on the PBS as a biosimilar and as an unrestricted benefit from 1 June 2021 to treat cancers such as colorectal, lung, cervical, and ovarian cancer The PBS listing criteria have been changed from Streamlined to Unrestricted on the recommendation of the PBAC, ...

Already a member?

Login to keep reading.

© 2022 the limbic